Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Detection of cell viability
研究概览
简要总结
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form
排除标准
- •Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study.
- •Other investigators believe that patients who are not suitable for this study group
研究组 & 干预措施
Triple Negative Breast Cancer
干预措施: Pyrrolidine (Drug)
Triple Negative Breast Cancer
干预措施: Ixabepilone (Drug)
HER2+ Breast Cancer
干预措施: Cyclophosphamide (Drug)
ER+ Breast Cancer
干预措施: Trastuzumab (Drug)
ER+ Breast Cancer
干预措施: Doxorubicin Hydrochloride (Drug)
ER+ Breast Cancer
干预措施: Epirubicin hydrochloride (Drug)
Triple Negative Breast Cancer
干预措施: Fluorouracil (Drug)
Triple Negative Breast Cancer
干预措施: Paclitaxel (Drug)
Triple Negative Breast Cancer
干预措施: Gemcitabine (Drug)
Triple Negative Breast Cancer
干预措施: Cisplatin (Drug)
Triple Negative Breast Cancer
干预措施: Tamoxifen citrate (Drug)
Triple Negative Breast Cancer
干预措施: Vinorelbine tartrate (Drug)
Triple Negative Breast Cancer
干预措施: Cyclophosphamide (Drug)
Triple Negative Breast Cancer
干预措施: Recombinant Human Endostatin (Drug)
Triple Negative Breast Cancer
干预措施: Pirarubicin hydrochloride (Drug)
HER2+ Breast Cancer
干预措施: Ear particles (Drug)
HER2+ Breast Cancer
干预措施: Trastuzumab (Drug)
HER2+ Breast Cancer
干预措施: Doxorubicin Hydrochloride (Drug)
HER2+ Breast Cancer
干预措施: Epirubicin hydrochloride (Drug)
HER2+ Breast Cancer
干预措施: Fluorouracil (Drug)
HER2+ Breast Cancer
干预措施: Paclitaxel (Drug)
HER2+ Breast Cancer
干预措施: Aidi Injection (Drug)
HER2+ Breast Cancer
干预措施: Gemcitabine (Drug)
HER2+ Breast Cancer
干预措施: Cisplatin (Drug)
HER2+ Breast Cancer
干预措施: Recombinant Human Endostatin (Drug)
HER2+ Breast Cancer
干预措施: Pirarubicin hydrochloride (Drug)
HER2+ Breast Cancer
干预措施: Pyrrolidine (Drug)
HER2+ Breast Cancer
干预措施: Ixabepilone (Drug)
HER2+ Breast Cancer
干预措施: Tamoxifen citrate (Drug)
HER2+ Breast Cancer
干预措施: Vinorelbine tartrate (Drug)
HER2+ Breast Cancer
干预措施: Carboplatin (Drug)
HER2+ Breast Cancer
干预措施: Methotrexate (Drug)
HER2+ Breast Cancer
干预措施: Eribulin mesylate (Drug)
HER2+ Breast Cancer
干预措施: Toremifene citrate (Drug)
HER2+ Breast Cancer
干预措施: Anastrozole (Drug)
HER2+ Breast Cancer
干预措施: Letrozole (Drug)
HER2+ Breast Cancer
干预措施: Exemestane (Drug)
HER2+ Breast Cancer
干预措施: Fulvestrant (Drug)
HER2+ Breast Cancer
干预措施: Olaparib (Drug)
HER2+ Breast Cancer
干预措施: Bevacizumab (Drug)
HER2+ Breast Cancer
干预措施: Apatinib mesylate (Drug)
HER2+ Breast Cancer
干预措施: Pattozumab (Drug)
HER2+ Breast Cancer
干预措施: Capecitabine (Drug)
ER+ Breast Cancer
干预措施: Fluorouracil (Drug)
ER+ Breast Cancer
干预措施: Paclitaxel (Drug)
ER+ Breast Cancer
干预措施: Gemcitabine (Drug)
ER+ Breast Cancer
干预措施: Cisplatin (Drug)
ER+ Breast Cancer
干预措施: Recombinant Human Endostatin (Drug)
ER+ Breast Cancer
干预措施: Pirarubicin hydrochloride (Drug)
ER+ Breast Cancer
干预措施: Pyrrolidine (Drug)
ER+ Breast Cancer
干预措施: Ixabepilone (Drug)
ER+ Breast Cancer
干预措施: Tamoxifen citrate (Drug)
ER+ Breast Cancer
干预措施: Vinorelbine tartrate (Drug)
ER+ Breast Cancer
干预措施: Carboplatin (Drug)
ER+ Breast Cancer
干预措施: Methotrexate (Drug)
ER+ Breast Cancer
干预措施: Eribulin mesylate (Drug)
ER+ Breast Cancer
干预措施: Toremifene citrate (Drug)
ER+ Breast Cancer
干预措施: Anastrozole (Drug)
ER+ Breast Cancer
干预措施: Letrozole (Drug)
ER+ Breast Cancer
干预措施: Exemestane (Drug)
ER+ Breast Cancer
干预措施: Fulvestrant (Drug)
ER+ Breast Cancer
干预措施: Olaparib (Drug)
ER+ Breast Cancer
干预措施: Bevacizumab (Drug)
ER+ Breast Cancer
干预措施: Apatinib mesylate (Drug)
ER+ Breast Cancer
干预措施: Pattozumab (Drug)
ER+ Breast Cancer
干预措施: Capecitabine (Drug)
ER+ Breast Cancer
干预措施: Ear particles (Drug)
ER+ Breast Cancer
干预措施: Aidi Injection (Drug)
ER+ Breast Cancer
干预措施: Cyclophosphamide (Drug)
Triple Negative Breast Cancer
干预措施: Trastuzumab (Drug)
Triple Negative Breast Cancer
干预措施: Doxorubicin Hydrochloride (Drug)
Triple Negative Breast Cancer
干预措施: Epirubicin hydrochloride (Drug)
Triple Negative Breast Cancer
干预措施: Carboplatin (Drug)
Triple Negative Breast Cancer
干预措施: Methotrexate (Drug)
Triple Negative Breast Cancer
干预措施: Eribulin mesylate (Drug)
Triple Negative Breast Cancer
干预措施: Toremifene citrate (Drug)
Triple Negative Breast Cancer
干预措施: Anastrozole (Drug)
Triple Negative Breast Cancer
干预措施: Letrozole (Drug)
Triple Negative Breast Cancer
干预措施: Exemestane (Drug)
Triple Negative Breast Cancer
干预措施: Fulvestrant (Drug)
Triple Negative Breast Cancer
干预措施: Olaparib (Drug)
Triple Negative Breast Cancer
干预措施: Bevacizumab (Drug)
Triple Negative Breast Cancer
干预措施: Apatinib mesylate (Drug)
Triple Negative Breast Cancer
干预措施: Pattozumab (Drug)
Triple Negative Breast Cancer
干预措施: Capecitabine (Drug)
Triple Negative Breast Cancer
干预措施: Ear particles (Drug)
Triple Negative Breast Cancer
干预措施: Aidi Injection (Drug)
结局指标
主要结局
Detection of cell viability
时间窗: 8 weeks before neoadjuvant chemotherapy
1. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration.
次要结局
- Detection of in vitro model drug sensitivity(8 weeks before neoadjuvant chemotherapy)
- Clinical efficacy assessment according to RECIST criteria(8 weeks before neoadjuvant chemotherapy)